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Abstract 
Background: Perfluoroalkyl substances (PFASs) are persistent synthetic compounds that have 
been environmental contaminants since the 1950s.  Exposure in the general population can be 
through food and water ingestion, use of non-stick cookware, and dust from stain-resistant 
carpet.  Studies have suggested PFASs act as endocrine disrupters and to affect liver and immune 
function, as well as cause increases in serum lipid levels. 
Objective: To explore the association between six common detectable PFASs and the metabolic 
syndrome (MetS) in United States (U.S.) adults. 
Methods: Data from 739 participants aged 20 years and older from the 2013-2014 National 
Health and Nutrition Examination Survey (NHANES) were analyzed.  Descriptive analysis was 
performed on the dataset.  Univariate and multivariable logistic regression analysis was used to 
determine independent association between the serum PFASs and MetS controlling for 
confounders including age, ethnicity, income, smoking status, and gender. 
Results: In the descriptive analysis, the overall prevalence of MetS in the sample population 
(49.5%) was higher than previously reported in the literature for U.S. adults, but distribution 
remained relatively equal between males (48.9%) and females (50.1%).  In unadjusted logistic 
regression analysis, each of the six PFASs showed a positive association with MetS, but only 
PFOS-branched (p < .001) and PFHxS (p = .019) were statistically significant.  However, after 
controlling for confounders, no significant association between the presence of PFASs and MetS 
was noted. 
Conclusion: In U.S. adults aged 20 and older, current serum concentrations of PFASs are not 
significantly associated with MetS. 
 Keywords: perfluoroalkyl substances, NHANES, public health, metabolic syndrome  
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The Association of PFASs Exposure and Metabolic Syndrome in U.S. Adults 
Perfluoroalkyl and polyfluoroalkyl substances (PFASs) are a collection of persistent and 
stable synthetic compounds which were first manufactured in the 1950s (Lin, Chen, Lin, & Lin, 
2009).  Due to their heat stability and water and stain-proofing, their use became very wide-
spread in consumer products.  PFASs can be found in non-stick cookware, stain-resistant fabrics 
and carpets, waterproofing for fabrics, firefighting materials (firefighting foams), and many other 
areas of industry due to their ability to reduce friction. 
The United States (U.S.) Environmental Protection Agency (EPA) considers PFASs as 
emerging contaminants based on published research, suggesting human health and 
environmental health concerns.  Since PFASs are stable, they are very persistent in the 
environment (Lau et al., 2007).  This also means that since their natural breakdown is slow and 
their presence in the environment is high due to lack of historic regulation, they pose a risk of 
bioaccumulation in animals, and they can enter the human food supply.  Water supply 
contamination and transfer from food packaging and cookware into food are also potential routes 
of human exposure. 
Since the year 2000, the EPA has been working with industry to phase out the use of 
PFASs (specifically PFOA and PFOS) in order to reduce the environmental burden and human 
exposure.  Previous studies using the National Health and Nutrition Examination Survey 
(NHANES) data have shown that 97% of the U.S. population had detectable levels of PFASs in 
their serum (Hu et al., 2016).  These blood levels appear to be trending down in the general 
population in recent years, likely due directly to the efforts by the EPA to limit its use in 
manufacturing (Fitz-Simon et al., 2013). 
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PFASs remain in the human body for years before they can be fully excreted.  The half-
lives for PFASs range from two to nine years (Lau et al., 2007).  Health studies in humans and 
animals suggest that PFASs are endocrine disruptors (can affect metabolism), have a negative 
effect on the immune system (which can lead to cancer), cause organ dysfunction 
(liver/pancreas) and can cause developmental problems in offspring (Lau et al., 2007).   
Metabolic syndrome (MetS), a group of risk factors that predisposes to cardiovascular 
disease (CVD), is characterized by hypertension, hyperglycemia, hypertriglyceridemia, reduced 
high-density lipoprotein (HDL) levels, and abdominal obesity (Huang, 2009; Moore, Chaudhary, 
& Akinyemiju, 2017).  MetS prevalence in the U.S. is approximately 33% (Aguilar, Bhuket, 
Torres, Liu, & Wong, 2015), which is higher than the worldwide prevalence of approximately 
25% (Nolan, Carrick-Ranson, Stinear, Readings, & Dalleck, 2017).   
Research Question 
What impact do PFASs (perfluoroalkyl and polyfluoroalkyl substances) exposure have on 
the development of MetS among the adult population (≥ 20 years) in the U.S.?  Since PFASs 
have been shown to interfere with endocrine activity in humans and increase cholesterol levels, 
we hypothesize that there will be an association between detectable PFASs levels in serum and 
the presence of MetS in adults aged 20 years and greater within the U.S. 
Literature Review 
Metabolic Syndrome 
Metabolic Syndrome (MetS) is a clustering of risk factors for developing atherosclerotic 
cardiovascular disease and is composed of: elevated waist circumference, elevated triglycerides 
(TGs), reduced HDL, elevated blood pressure, and elevated fasting glucose (Huang, 2009; 
Moore et al., 2017).  In 2001, the National Cholesterol Education Program (NCEP) Adult 
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Treatment Plan (ATP) III devised criteria for defining MetS in the adult population (Table 1).  
The criteria are similar to the World Health Organization (WHO) criteria from 1998 and the 
European Group for the Study of Insulin Resistance (EGIR) of 1999, but it does not require any 
one criterion, as the previous definitions had.  Instead it uses easily obtained laboratory and 
clinical measurements that clinical physicians worldwide can acquire and are simple and easy to 
remember (Huang, 2009).  The specific criteria for MetS are any three of the five modified 
NCEP ATP III criteria noted in Table 1 (Department of Health and Human Services [DHHS], 
Centers for Disease Control and Prevention [CDC], 2009, 2009). According to guidelines from 
the National Heart, Lung, and Blood Institute (NHLBI) and the American Heart Association 
(AHA), metabolic syndrome is diagnosed when a patient has at least three of the five conditions 
described in Table 1 (Grundy et al., 2005). 
Perfluoroalkyl and Polyfluoroalkyl substances (PFASs) 
 Due to the manufacturing boom following the end of World War II, the environment in 
which humans live, work, and play has undergone many changes.  This has increased human 
exposures to many chemicals and compounds not previously known to man, and our 
understanding of the long-term health risks of these exposures is not always clear (Stubleski et 
al., 2016).  Some of these chemicals have been shown to act as endocrine disruptors in humans 
and a growing hypothesis is that these chemicals may be to blame in part for the increasing 
prevalence of MetS (Nelson, Hatch, & Webster, 2010).  One such class of chemicals is PFASs.  
PFASs have been widely used in commercial and industrial applications since the 1950s due to 
their stability, water and oil repellency, and stain resistant nature.  The main PFASs congeners 
are: perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorononanoic 
acid (PFNA), and perfluorohexane sulfonic acid (PFHxS) (Stubleski et al., 2016). 
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Exposure to PFASs 
Human exposure to PFASs is broad, since these chemicals have been used throughout 
industry for more than 65 years and due to their stable nature, have become ubiquitous in the 
environment.  Industrial sites, military fire training areas, and wastewater treatment facilities 
have all been noted to be areas of growing concern for environmental contamination (Hu et al., 
2016).  All routes of exposure are not known, but the most common routes of exposure are 
through diet (from food packaging, the use of non-stick cookware, or possibly through 
bioaccumulation in food sources), contaminated drinking water sources, and household dust via 
particulates from stain-resistant carpeting (Nelson et al., 2010; Stubleski et al., 2016).  Once in 
the human body, PFASs haven’t been shown to undergo biotransformation.  Unlike other 
chemical contaminants PFASs are not stored in fatty tissue.  Instead, they bind to plasma 
proteins and are slowly excreted through renal clearance.  Elimination half-lives for each 
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chemical differ and are as follows: PFOA has the shortest at approximately 3.8 years, PFOS at 
approximately 5.4 years, and PFHxS the longest at 8.5 years (DHHS CDC, 2009).  
PFASs and Endocrine Function 
Due to the structural similarities between PFASs and fatty acids, PFASs have been shown 
to bind to peroxisome proliferator-activated receptors (PPARs), which have a role in lipid 
metabolism and adipogenesis (Nelson et al., 2010).  With evidence that PFASs bind to PPARs 
and previous studies showing that PFASs exert influence as endocrine-disruptors, it is 
conceivable that there may be an association between human serum PFASs concentrations and 
the prevalence of metabolic syndrome in the U.S. adult population.  Most of the existing 
epidemiological studies report a positive association between PFASs and lipids.  Evidence from 
general population and occupational settings suggests that PFOA may be associated with 
increased low-density lipoprotein (LDL) and total cholesterol levels (Steenland et al., 2010). 
Evidence regarding PFASs and adverse cardiometabolic health outcomes is emerging.  
Among U.S. adults, serum PFOA levels were associated with higher peripheral artery disease 
and self- reported CVD (Shankar, Xiao, & Ducatman, 2012); this study did not assess other 
PFASs.  
Evidence from laboratory studies has revealed that PFASs exposure is related to 
oxidative stress and endothelial dysfunctions which are regarded subclinical risk factors for 
cardiovascular and metabolic diseases (Lau et al., 2007).  In human studies, although health 
effects of PFASs were inconsistent, a positive association between PFOA, PFOS, PFNA and 
total cholesterol, low density cholesterol, and poor glucose homeostasis has been noted (Lau et 
al., 2007; Lin et al., 2009; Fitz-Simons et al., 2013; Liu, Wen, Chu, & Lin, 2018). These are 
antecedents to cardiometabolic pathology.    
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Methods 
Data Source and Study Sample 
Data for 2013-2014 were obtained from the freely available National Health and 
Nutrition Examination Survey (NHANES), which is a population-based survey.  NHANES 
collects health and nutritional information about noninstitutionalized U.S. individuals every two 
years.  The survey’s goal is to collect a representative sample of the U.S. population.  All survey 
operations manuals, brochures and consent documents for the 2013-2014 dataset are publicly 
available on the NHANES website as part of the CDC. 
The total NHANES population sample for 2013-2014 was 9,813 non-institutionalized 
U.S. civilians that were consented, interviewed and had examinations performed at 30 different 
mobile study sites throughout the U.S.  Participants were sent to a mobile examination center 
(MEC) where laboratory measurements, physical assessments, and examinations were 
conducted.  Laboratory testing of collected samples was conducted by the Division of Laboratory 
Sciences, National Center for Environmental Health, CDC, Atlanta, GA (CDC NCHS, 2018). 
From the 2013-2104 NHANES dataset, individuals with available serum PFASs levels, 
and available data for the five components of MetS (triglycerides, HDL, glucose, waist 
circumference, and blood pressure) were included in the analysis.  (NHANES protocol randomly 
analyzed serum PFASs in 1/3 of the 2013-2014 participants that were over 12 years of age.)  
After filtering out individuals less for age 20 years for missing values in the dataset for the MetS 
criteria, PFASs serum levels, and the confounders listed below, the final sample size was N = 
739 (CDC NCHS, 2018). 
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Confounders 
Socioeconomic and sociodemographic information (i.e., age, race/ethnicity, gender, 
smoking status, and income) were collected by trained interviewers using the in-home NHANES 
Family Questionnaire via the Computer- Assisted Personal interview (CAPI) system. 
Race/Ethnicity was reported as Hispanic, non-Hispanic White, non-Hispanic Black, and other 
multi- racial (referent category).  
Examination and Laboratory Procedures 
Height, weight, and waist circumference were measured by trained health technicians 
assisted by a recorder using a stadiometer for height in meters (m), a retractable steel measuring 
tape for waist circumference measurements in centimeters (cm), and a digital weight scale, either 
portable or built into the floor of the MEC, for weight in kilograms (kg) (CDC NCHS, 2015a).  
All BP determinations (systolic and diastolic) were taken in the MEC.  After the 
participant had rested quietly in a seated position for five, three consecutive blood pressure 
readings were obtained using the right arm unless there was an issue with that arm.  If any of the 
participants had any issues with both arms (like rashes, gauze dressings, casts, edema, paralysis, 
tubes, open sores or wounds, withered arms, a-v shunts, radical mastectomy, or if the blood 
pressure cuff did not fit on the arm) they were excused from this portion of the exam (CDC 
NCHS, 2015b). 
Triglycerides, fasting glucose, HDL-C serum levels were run on all participants bloods 
samples that were collected at the MEC and sent to the contracted testing lab, in this case 
Collaborative Laboratory Services, LLC (CDC NCHS, 2013). 
Tobacco smoking status was determined objectively utilizing the serum cotinine levels 
obtained at the MEC, with the categories broken down as ‘Non-smoker’ (referent category) 
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(serum cotinine level < 1 ng/mL), ‘Environmental Tobacco Smoke’ exposure (serum cotinine 
level 1 – 10 ng/mL), and ‘Smoker’ (serum cotinine level > 10 ng/mL) (DHHS CDC, 2009). 
Metabolic Syndrome Determination 
 The clinical criteria for the determination of whether a participant had MetS are listed in 
Table 1.  These criteria are based on the 2005 NCEP ATP III update (Grundy et al., 2005).  A 
subject was considered to meet the criteria for metabolic syndrome if they had at least three of 
the five criteria.  The male and female participants were characterized as having MetS when they 
met NECP recommended gender specific criteria (Table 1), or were taking medication (lowering 
BP, cholesterol, blood sugar) or treatment such as insulin.  The official NHANES variable names 
used in this analysis can be found in Appendix A.  
PFASs Concentration Measured via Serum Analysis 
PFASs chemicals or PFCs in previous year datasets were analyzed from the blood draw 
performed at the MEC.  A short description of the laboratory methodology used by the 
laboratory is as follows:  Online-solid phase extraction coupled to High Performance Liquid 
Chromatography-Turbo Ion Spray ionization-tandem Mass Spectrometry was used for the 
quantitative detection of PFAS including PFHxS, (PFNA), linear PFOA (n-PFOA), sum of 
branched isomers of PFOA (Sb-PFOA, branched PFOA isomers), linear PFOS (n-PFOS), and 
sum of perfluoromethylheptane sulfonate isomers (Sm-PFOS, monomethyl branched PFOS 
isomers).  Briefly, after dilution with formic acid, one aliquot of 100 μL of serum was injected 
into a commercial column switching system allowing for concentration and chromatographic 
separation of the analytes.  Detection and quantification were done using tandem mass 
spectrometry (Kuklenyik, Needham, & Calafat, 2005).  The lower limit of detection (LLOD) for 
each PFAS was 0.10 ng/mL.  If a sample had analytic results below the LLOD, an imputed value 
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was placed in the database for that sample by the NHANES study designers.  This value was 
determined by using the formula (LLOD/sqrt2), which yielded a result of 0.07 ng/mL for each of 
the six PFASs (CDC NCHS, 2016a; CDC NCHS, 2016b). 
Statistical Analysis  
Data analyses were performed using the Statistical Package for the Social Science (SPSS) 
version 25.0 (IBM Corp, Released 2016).  Analysis was presented for the overall data set and 
also by gender.  Descriptive statistics were computed overall and across gender for continuous 
variables including measures of centrality (mean or median) and dispersion (standard deviation 
or interquartile range) (age, BMI, PFASs).  Frequency distributions (number and proportion) was 
computed for categorical variables (age, smoking, income, and race/ethnicity) and the MetS 
criteria (blood pressure, serum triglycerides, HDL level, waist circumference, and fasting blood 
sugar levels.)  
Across gender, statistical significance for continuous variables was tested using Student’s 
2-tailed t-test for normally distributed variables (age and BMI) and the Mann-Whitney U test for 
non-normal variables (PFASs) at the α = 0.05 level of significance.  To test statistical 
significance for categorical variables across gender, the chi-square test was used (ethnicity, 
smoking status, income).  As PFASs were not distributed normally, natural log-transformation 
was performed.   
Univariate logistic regression was performed with MetS as the outcome or dependent 
variable (yes/no) and each of the individual natural log-transformed PFASs concentrations as a 
single predictor.  In the second model the model was adjusted for age.  In the third model, the 
data was adjusted for age plus income levels, ethnicity, and smoking status.  In the final model, 
we adjusted for all available covariates including age, race/ethnicity, smoking (serum cotinine), 
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age, annual household income and added gender as the final variable.  The Odds Ratio (OR) and 
95% Confidence Interval (CI) of risk of MetS per unit change in log-transformed serum PFASs, 
with the two-tailed p-value used at an α = 0.05 significance level.  A forest plot was generated in 
Microsoft Excel to show the OR and 95% CI each of the six PFASs in unadjusted and 
multivariable adjusted models.  
Results 
Descriptive Statistics 
The descriptive statistics of our sample aged 20 years or greater are reported in Table 2, 
overall (N = 739) and by gender.  The mean age in both genders was comparable (males: 49.7 
years, females: 49.9 years).  The gender distribution in this sample population was relatively 
equal, with 48.4% male and 51.6% female.  Race distribution was predominantly non-Hispanic 
White at 43.8%, and the predominant household annual income was > $55,000 at 38.2%.  
Smoking status, revealed that 72.3% were non-smokers, 23.5% were smokers, and 4.2% were 
exposed to environmental tobacco smoke.  The mean BMI for both males and females fell within 
the ‘overweight’ category with mean values of 28.4 for males and 29.4 for females.  Females in 
this sample were slightly heavier as compared to males and had an average 1.97 points higher 
BMI than their male counterparts.  This difference was statistically significant (p = .039). 
The prevalence of MetS was 49.5%, and nearly evenly distributed between males 
(48.9%) and females (50.1%).  In this population, 10.6% used diabetes medications or insulin, 
26% used cholesterol medications, and 31.4% used blood pressure medications.  When 
comparing of the individual MetS criteria by gender, more males met MetS criteria for elevated 
triglycerides, and higher fasting blood glucose.  In contrast, more females met the MetS criteria 
for larger waist circumference and low HDL; however, both males and females had relatively 
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equal distribution of high blood pressure defined by MetS criteria.  PFASs levels obtained from 
the NHANES 2013-2014 dataset were analyzed as shown in Table 2.  Males had higher serum 
PFASs concentrations compared to females, which was statistically significant in branched 
PFOS (p < .001), linear PFOA (p = .001), PFHxS (p < .001) and PFNA (p = .014).  However, 
linear PFOS levels were not significantly different between males and females.  
PFASs AND METABOLIC SYNDROME  15 
 
 
PFASs AND METABOLIC SYNDROME  16 
Univariate and Multivariable Logistic Regression Analysis 
As shown in Table 3, in univariate logistic regression all PFASs showed an odds ratios 
MetS greater than one, suggesting an increased risk of having MetS, but only two of these 
PFASs reached statistical significance [PFOS-branched (OR=1.32, 95% CI=1.13-1.53, p < .001), 
PFHxS (OR=1.20, 95% CI=1.03-1.39, p < .019)].  However, the significant associations between 
MetS and these two variables was lost after adjusting for confounders.  Similarly, in 
multivariable analysis, none of the other six PFASs had statistically significant association with 
MetS.  These results did not change after further adjustment for gender.  Figures 1 and 2 
illustrate the data using forest plots to show the OR and 95% CI for each of the six PFASs in 
unadjusted and multivariable adjusted models, respectively. 
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Figure 1.  Unadjusted logistic regression showing association of log-transformed PFASs with 
metabolic syndrome. 
 
 
Figure 2.  Multivariable adjusted logistic regression showing association of log-transformed 
PFASs with metabolic syndrome.   
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Sensitivity Analysis 
 A sensitivity analysis was conducted to explore if excluding participants with serum 
PFAS <LOD modified the results.  In unadjusted models, branched PFOS and PFHxS showed a 
higher risk of MetS (p < .001 for both).  In contrast, PFNA showed a lower risk (p = .047) of 
MetS in age adjusted model.  However, in multivariable analysis adjusting for confounders, none 
of the six PFAS indicated a significant risk of MetS.  Excluding participants with serum levels 
less than LOD for PFAS values did not change our conclusion. 
Discussion 
 In this cross-sectional analysis of the NHANES 2013-2014 data, although all six PFASs 
tested had suggested there was a significant association with MetS in U.S. adults aged 20 years 
and older in the unadjusted models, this association was not statistically significant after 
adjusting for confounders.   
 Previous studies have shown a positive association between elevated serum lipid levels 
and elevated PFOA and PFOS levels, and that that those abnormal lipid levels corrected over 
time as the PFASs levels in their serum decreased over time with natural clearance (Fitz-Simon 
et al., 2013).  However, the study by Fitz-Simon et al. (2013) was completed in a population with 
known elevated environmental exposure and not the U.S. general population exposure as 
explored in the current analysis.   
 An interesting observation in our analysis was that the prevalence of MetS in our studied 
population which is representative of the U.S. population, was near 50%.  According to 
published reports prevalence of MetS in the U.S. adult population has been gradually increasing 
over the years, as reported in a research letter in JAMA, May 2015, which showed that the 
prevalence of MetS in NHANES datasets rose from 32.9% in 2003-2004, to 34.7% in 2011-2012 
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(Aguilar et al., 2015).  In 2014, the highest MetS prevalence was 38.6% in Hispanics, 37.4% in 
non-Hispanic Whites, and over 50% for women and Hispanics over the age of 60 (Aguilar et al., 
2015).  Other recent international studies have reported a similar increasing magnitude of MetS 
prevalence.  An overall MetS prevalence above 50% in adults over 45 years of age was noted 
(Delavari, Forouzanfar, Alikhani, Sharifian, & Kelishadi, 2009), which was concurrent with our 
findings, suggesting the worldwide prevalence of MetS is on the rise. 
 Although the associations seen were not statistically significant, our findings showing a 
negative relationship between the PFASs and MetS after adjusting for confounding variables.  
These results match what others have seen in the same NHANES 2013-2014 dataset suggesting 
the presence of PFASs may infer some protection against low HDL levels, and high triglyceride 
levels, although the mechanism for this is yet unknown (Liu et al.., 2018).  
A sensitivity analysis was conducted to explore if excluding participants with serum 
PFAS <LOD modified the results.  In unadjusted models, PFOS-branched and PFHxS showed a 
higher risk of MetS (p < .001 for both).  In contrast, PFNA showed a lower risk (p = .047) of 
MetS in the age-adjusted model.  However, in multivariable analysis, none of the six PFAS 
variables indicated a significant risk of MetS.  The conclusion of the sensitivity analysis was that 
excluding those participants with serum levels of PFAS below LOD did not change the 
outcomes. 
Strengths 
The study had several strengths.  Data from NHANES, which is nationally representative, 
characterizing both genders and ethnicities, was used.  We adjusted for a number of confounding 
variables including lifestyle, and socioeconomic status.  Earlier publications from NHANES 
have reported association of MetS with two PFASs isomers (PFOA, PFOS) (Liu et al., 2018).  
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To our knowledge this is the first analysis in which two additional congeners (PFHxS, PFNA) 
were assessed regarding their impact on MetS.  
Limitations 
Our study had several limitations.  First, the cross-sectional design of the study does not 
allow us to infer any causation between PFAS and MetS.  Second, our study did not look at the 
effect of higher PFASs levels and metabolic syndrome specifically.  Instead, we focused on 
whether any presence of PFASs in the serum could have an association with metabolic 
syndrome.  Other studies have demonstrated a positive association between higher PFASs levels 
and glucose homeostasis, especially in adolescents (Lin et al., 2009), but we didn’t take 
adolescents into account for our analysis.  This could be an area of future research to see if there 
continues to be an association between higher levels of PFASs and MetS, especially in the adult 
population.  Also, we were unable to control for seafood intake, which is a significant source of 
PFASs exposure.   
Conclusion 
 According to the results of our study, the presence of PFASs in the serum of U.S. adults 
aged 20 years and greater does not have a statistically significant association with the prevalence 
of MetS.  Further study comprising of a larger dataset combining data from several survey cycles 
is needed to evaluate the effect of serum levels of PFASs on the prevalence of MetS.  
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Appendix C - List of Competencies Met in Integrative Learning Experience 
Wright State Program Public Health Competencies Checklist 
 
Assess and utilize quantitative and qualitative data. 
Apply analytical reasoning and methods in data analysis to describe the health of a community. 
Describe how policies, systems, and environment affect the health of populations. 
Evaluate and interpret evidence, including strengths, limitations, and practical implications. 
Demonstrate ethical standards in research, data collection and management, data analysis, and 
communication. 
 
Concentration Specific Competencies Checklist 
 
Population Health Concentration 
Demonstrate application of an advanced qualitative or quantitative research methodology. 
Demonstrate the ability to contextualize and integrate knowledge of a specific population health issue. 
 
 
